New possibilities for potent cancer immunotherapies with Nanolive solutions

We are thrilled to announce a groundbreaking scientific study authored by Mathieu Frechin and Daniel Olive, in collaboration with Aix Marseille Université, ImCheck therapeutics, and Nanolive. Their remarkable research on Vγ9Vδ2 T cells has opened up new possibilities for potent cancer immunotherapies.

In this study, they investigated the role of BTN2A1, a surface protein that binds to the Vγ9 chain of the γδ TCR, in modulating Vγ9Vδ2 T cell functions. The team discovered a monoclonal anti-BTN2A1 agonist antibody called 107G3B5, which demonstrated remarkable potential in enhancing Vγ9Vδ2 T cell responses.

Through the use of cutting-edge computer vision strategies applied to holotomographic microscopy videos, the researchers observed that 107G3B5 significantly improved the interaction between Vγ9Vδ2 T cells and target cells.

This enhancement occurred both quantitatively and qualitatively, paving the way for more effective immunotherapies against hematological and solid cell lines. Furthermore, this antibody also exhibited positive effects on primary cells from adult acute lymphoblastic leukemia patients.

The study also shed light on the mechanisms behind this improved response. The activated Vγ9Vδ2 T cells, triggered by 107G3B5, induced caspase 3/7 activation in tumor cells, leading to their death through pyroptosis. This remarkable discovery highlights the potential of targeting BTN2A1 with 107G3B5, not only in enhancing the Vγ9Vδ2 T cell antitumor response but also in promoting immunogenic cell death.

We applaud the collaborative efforts of Mathieu Fréchin, Daniel Olive, Christophe Dubois, Aix-Marseille University, ImCheck Therapeutics, and Nanolive SA, which have yielded groundbreaking insights into cancer immunotherapy. This research has the potential to revolutionize the field and bring us closer to powerful new treatment options for cancer patients.

Stay tuned for more updates as we continue to explore the incredible possibilities that arise from this extraordinary research collaboration!

Read our latest news

Newsletter May 2024: In vitro drug candidate profiling

Newsletter May 2024: In vitro drug candidate profiling

Welcome to the first edition of the AI for Live Cell Insights newsletter, bringing you the latest live cell analyses powering drug discovery and cosmetics development. Each month, we will explore a new application of AI-based cellular analysis for label-free live cell...

Subscribe to our newsletter

  • This field is for validation purposes and should be left unchanged.